Trial Radar KI | ||
|---|---|---|
Die klinische Studie NCT05613504 für Hitzewallungen, Brustkrebs, Akupunktur ist noch nicht rekrutierend. In der Kartenansicht des Klinische Studien Radar und den KI-Entdeckungstools finden Sie alle Details. Oder stellen Sie hier Ihre Fragen. | ||
Eine Studie entspricht den Filterkriterien
Kartenansicht
Study of Acupuncture in the Treatment of Hot Flashes in Patients With Hormone Receptor-positive Breast Cancer. 90
Die Details der klinischen Studie sind hauptsächlich auf Englisch verfügbar. Trial Radar KI kann jedoch helfen! Klicken Sie einfach auf 'Studie erklären', um die Informationen zur Studie in der ausgewählten Sprache anzuzeigen und zu besprechen.
Die klinische Studie NCT05613504 ist eine interventionsstudie zur Untersuchung von Hitzewallungen, Brustkrebs, Akupunktur und hat den Status noch nicht rekrutierend. Der Start ist für 1. Dezember 2022 geplant, bis 90 Teilnehmer aufgenommen werden. Durchgeführt von Nanjing University of Traditional Chinese Medicine wird der Abschluss für 1. Dezember 2027 erwartet. Die Daten von ClinicalTrials.gov wurden zuletzt am 16. November 2022 aktualisiert.
Kurzbeschreibung
This study intends to further evaluate the efficacy of acupuncture by comparing the intervention effects of different acupuncture treatment regimens on hot flashes in breast cancer ; and to explore the central effect regulation mechanism of acupuncture intervention on hot flashes based on integrated PET/MRI technology.
Ausführliche Beschreibung
This topic combines the theory of "unblocking the governor and warming the yang" with the important findings of modern research, that is, the important mechanism of the spine in the pathogenesis of breast cancer, and innovatively proposes the technique of unblocking the governor and treating the spine. Prospective clinical intervention research in rehabilitation, objectively evaluate the clinical efficacy, advantages...Mehr anzeigen
Offizieller Titel
A Randomized Controlled Trial Study of Acupuncture in the Treatment of Hot Flashes in Patients With Hormone Receptor-positive Breast Cancer.
Erkrankungen
HitzewallungenBrustkrebsAkupunkturWeitere Studien-IDs
- 2022JC-55-1
NCT-Nummer
Studienbeginn (tatsächlich)
2022-12-01
Zuletzt aktualisiert
2022-11-16
Studienende (vorauss.)
2027-12-01
Geplante Rekrutierung
90
Studientyp
Interventionsstudie
PHASE
Nicht zutreffend
Status
Noch nicht rekrutierend
Stichwörter
breast cancer
Acupuncture
Integrated PET/MRI technology
Hot flashes
Acupuncture
Integrated PET/MRI technology
Hot flashes
Primäres Ziel
Behandlung
Zuteilungsmethode
Randomisiert
Interventionsmodell
Parallel
Verblindung
Dreifach verblindet
Studienarme/Interventionen
| Teilnehmergruppe/Studienarm | Intervention/Behandlung |
|---|---|
Aktives VergleichspräparatTreatment group A Treatment group A was given endocrine and acupuncture treatment for 8 weeks (24 times in total, 3 times a week); followed up for 16 weeks, no acupuncture treatment. | Akupunkturbehandlung Acupoint selection: 4 general points + syndrome differentiation acupoints (select or replace 2-4 acupoints according to symptom 1, select 1-2 acupoints according to symptom 2 and symptom 3), and adjust acupoints according to symptoms every week.
Frequency: 3 times a week (once every other day) for a total of 8 weeks of continuous treatment.
Operation: Use a one-time sterile acupuncture needle (0.30×40mm, Huatuo bra...Mehr anzeigen |
Schein-VergleichspräparatTreatment group B Treatment group B was given endocrine and sham acupuncture treatment for 8 weeks, followed up for 16 weeks, no acupuncture during the period, and after 16 weeks, received standardized acupuncture for 8 weeks (24 times in total, 3 times a week). | Scheinakupunkturbehandlung Acupoint selection: According to the selected acupoints of the electroacupuncture group, 5-7 positions were selected at the non-meridian and non-acupoint points(points with less nerve distribution, sparseness, and rich muscles).
Frequency: 3 times a week (once every other day) for a total of 8 weeks of continuous treatment.
Operation: ① Shallow needling scheme: use a disposable sterile acupuncture needle, insert th...Mehr anzeigen |
Keine Interventioncontrol The control group was given conventional adjuvant endocrine therapy, premenopausal patients received tamoxifen therapy, and postmenopausal patients received aromatase inhibitor or tamoxifen therapy. | Nicht zutreffend |
Hauptergebnismessungen
Nebenergebnismessungen
| Ergebnismessung | Beschreibung der Messung | Zeitrahmen |
|---|---|---|
Change in cancer therapy functional assessment | Cancer therapy functional assessment scores will be assessed with Cancer Therapy Functional Assessment-Breast cancer, version 4.The minimum value is 0 , and the maximum value is 185. The higher scores mean a worse outcome. | Baseline, 8, 12，24 weeks later |
Change in acupuncture efficacy expectation assessment | Acupuncture efficacy expectation assessment scores will be assessed with acupuncture efficacy expectation assessment. The minimum value is 0 , and the maximum value is 20. The higher scores mean a better outcome. | Baseline, 8, 12，24 weeks later |
Change of functional connectivity of whole brain | Functional connectivity will be measured with magnetic resonance imaging based on blood oxygen level dependence. | Baseline, 8, 12，24 weeks later |
Change of metabolism of glucose in the brain | Accumulation of 18F-fluorodeoxyglucose(18F-FDG) will be analyzed by time-related Positron emission tomography. | Baseline, 8, 12，24 weeks later |
Change of hot flash severity | Hot flash severity will be assessed with hot flash scores each week. There are four levels of severity： Mild: Duration: Less than five minutes. Symptoms: warmth, discomfort, flushing. Moderate: Duration: Up to fifteen minutes. Symptoms: warmth in head, neck, ears, or body; tense, tight muscles; clammy skin; change in heart rate or rhythm; light sweating; dry mouth.
Severe: Duration: Up to twenty minutes. Symptoms: Fever, sometimes like a crucible or burning sensation; change in heart rate or rhythm; feeling faint; headache; heavy sweating.
Very severe: Duration: Up to forty-five minutes. Symptoms: boiling heat; constant sweating; trouble breathing; feeling faint, dizzy; leg cramps or feeling cramps; change in heart rate; stomach upset.
The greater severity mean a worse outcome. | Baseline, 8, 12，24 weeks later |
| Ergebnismessung | Beschreibung der Messung | Zeitrahmen |
|---|---|---|
Change in sleep | Sleep scores will be assessed with Pittsburgh sleep quality index.The minimum value is 9, and the maximum value is 36. The higher scores mean a worse outcome. | Baseline, 8, 12，24 weeks later |
Teilnahme-Assistent
Eignungskriterien
Zugelassene Altersgruppen
Erwachsene, Ältere Erwachsene
Mindestalter
30 Years
Zugelassene Geschlechter
Weiblich
- Aged 30-75 years old;
- Adjuvant hormone therapy (eg, tamoxifen and/or aromatase inhibitors) with or without ovarian function suppression has been administered for at least 4 weeks and is currently on treatment;
- Patients with persistent hot flashes for at least 4 weeks and with a frequency of more than 14 hot flashes per week (2 times per day) in the week before inclusion in the study, the weekly average hot flash composite score is 3-4;
- Patients after surgery and chemotherapy (if any);
- Eastern Cooperative Oncology Group score of 0-1 points.
- Sign the informed consent and participate in the clinical observation voluntarily.
- Tumor metastases, undergoing chemoradiotherapy or planning surgery;
- Pharmacological intervention for hot flashes with hot flash treatment drugs such as selective serotonin reuptake inhibitors (SSRIs) and/or anticonvulsants for at least 4 weeks prior to study initiation;
- Patients receiving phytoestrogens, tibolone or analogs, verapril, or specific homeopathic medicines;
- Started or changed adjuvant hormone therapy within the past week, or who planned to start or change adjuvant hormone therapy in the past 14 weeks, pregnant or breastfeeding patients;
- Bleeding or coagulation disorders with obvious uncontrolled infection
- Psychiatric illness or family history; neurological disorder or family history; seizure possibility or history of seizures.
Nanjing University of Traditional Chinese MedicineVerantwortliche Partei
Qianyan Liu, Hauptprüfer, Principal Investgator, Nanjing University of Traditional Chinese Medicine
Zentrale Studienkontakte
Kontakt: Lijun Bai, phd, 0086-15129034948, [email protected]
1 Studienstandorte in 1 Ländern
Jiangsu
Jiangsu Province Hospital of Traditional Chinese Medcine, Nanjing, Jiangsu, 210029, China
Lijun Bai, PHD, Kontakt, 0086-15129034948, [email protected]